Laura Bukavina, Urologic Oncologist at Cleveland Clinic, shared on X:
“New results from the CREST Study (NCT04165317) for HR-NMIBC: Adding sasanlimab to BCG induction + maintenance shows:
•32% decrease of EFS event (HR 0.68, p=0.0095)
•greater than 50% reduction in HG recurrence
•No difference in overall survival (OS interim HR 1.13, p=0.6791)”
The CREST Study (NCT04165317) evaluated the addition of sasanlimab to BCG induction and maintenance therapy in patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC). Results showed a 32% reduction in event-free survival events and over a 50% reduction in high-grade recurrence, with no significant difference observed in interim overall survival.
More posts featuring Laura Bukavina on OncoDaily.
